Barclays
IMVT icon

Barclays’s Immunovant IMVT Stock Holding History

Barclays’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Buy
39,471
+24,571
+165% +$749K ﹤0.01% 2522
2026
Q1 		$370K Sell
14,900
-217,426
-94% -$5.63M ﹤0.01% 3357
2025
Q4 		$5.91M Buy
232,326
+5,969
+3% +$133K ﹤0.01% 2086
2025
Q3 		$3.65M Sell
226,357
-44,993
-17% -$728K ﹤0.01% 2429
2025
Q2 		$4.34M Buy
271,350
+119,809
+79% +$1.81M ﹤0.01% 2250
2025
Q1 		$2.59M Sell
151,541
-158,789
-51% -$3.32M ﹤0.01% 2444
2024
Q4 		$7.69M Buy
310,330
+92,518
+42% +$2.62M ﹤0.01% 1783
2024
Q3 		$6.21M Buy
217,812
+119,372
+121% +$3.52M ﹤0.01% 1894
2024
Q2 		$2.6M Sell
98,440
-110,830
-53% -$3.15M ﹤0.01% 1952
2024
Q1 		$6.76M Buy
209,270
+41,277
+25% +$1.51M ﹤0.01% 1654
2023
Q4 		$7.08M Buy
+167,993
New +$6.18M ﹤0.01% 1809
2023
Q3 		– Sell
-2,286
Closed -$51.7K – 4645
2023
Q2 		$43.4K Buy
2,286
+2,200
+2,558% +$41K ﹤0.01% 3904
2023
Q1 		$1.33K Buy
+86
New +$1.49K ﹤0.01% 4913
2022
Q4 		– Sell
-6,000
Closed -$33K – 5315
2022
Q3 		$33K Buy
+6,000
New +$29.3K ﹤0.01% 3905

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's IMVT Position: Q2 2026 in Review

Barclays increased its Immunovant (IMVT) stake by 165% in Q2 2026, buying an estimated $749K and bringing the position to 39,471 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2522.

Barclays first reported a position in IMVT in Q3 2022 and has held it in 14 quarters since. The position peaked at $7.69M in Q4 2024. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Barclays held 39,471 shares of Immunovant worth $1.52M as of Q2 2026.
  • Barclays bought 24,571 Immunovant shares in Q2 2026, an estimated $749K.
  • Immunovant made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2522 holding.
  • Barclays first reported a position in Immunovant in Q3 2022 and has held it in 14 quarters since.
  • Barclays's Immunovant position peaked at $7.69M in Q4 2024.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.